CCN2 and Peritoneal Fibrosis: Since peritoneal fibrosis is already established by day 7 of the 21-day CG model27, we also examined the therapeutic potential of CTGF inhibition for peritoneal fibrosis by administering FG-3019 beginning 7 days after CG challenge onset in a therapeutic regimen.